2016 In Review: FDA Transparency, Claims Enforcement A One-Off?
This article was originally published in The Rose Sheet
Executive Summary
The Rose Sheet’s coverage of FDA’s warning letter crackdown and data sharing produced some of its most-read stories of 2016, based on online analytics. Legislative proposals and cosmetic safety issues in the US mainstream factored in the agency’s transparency work, a situation that may not repeat in the new year.
You may also be interested in...
Could Cosmetic Modernization Bill Jumpstart Anti-Aging Skin Care?
The Cosmetic Modernization Amendments of 2015, which could be relaunching imminently, had no shortage of industry-friendly provisions, but one proposal could be of particular interest to anti-aging skin-care marketers faced with slumping consumer demand – revision of the “cosmetic” definition under federal law to allow for limited structure/function claims.
FDA Warnings Slow, But Anti-Aging Claims Remain Class Action Targets
The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.
Freedom Caucus Hit List Includes Antibacterial Soap, Supplement Label Rules
The caucus of 36 conservative Republicans lists 200 rules passed during the Obama administration, or the that president established through executive orders, that it recommends striking altogether or changing to lessen industries' regulatory burden.